Top Industry Leaders in the Anemia Drugs Market
Latest Anemia Drugs Companies Update:
InSilico Medicine announced a breakthrough AI-driven discovery of a novel PHD inhibitor for anemia treatment. This potentially offers a new approach to targeting the underlying cause of anemia, particularly in cases where existing medications aren't effective. (October 26, 2023)
GSK's Jesduvroq (daprodustat) continues to gain traction as a novel anemia treatment for kidney disease patients. Approved in February 2023, this drug offers an alternative to erythropoiesis-stimulating agents (ESAs) and is already seeing adoption in some markets. (November 7, 2023)
No major M&A deals involving major anemia drug companies have been announced recently. However, smaller players in the field are actively acquiring technologies and expanding their portfolios. For example, Cygnus Technologies' acquisition of SiNica Bio strengthens their presence in the Asian HCP testing market, which can indirectly impact anemia drug development.
List of Anemia Drugs Key companies in the market
- Amgen Inc
- GlaxoSmithKline plc
- Bluebird bio
- Biocon
- GlycoMimetics Inc
- Regen biopharma Inc
- Bayer AG
- Acceleron Pharma
- Eli Lilly and company